Captura Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Captura Biopharma is addressing a significant unmet medical need in radiation emergency preparedness with its lead oral therapeutic candidate, C2E2. The company leverages a team with deep pharmaceutical development, regulatory, and emergency medicine expertise to advance a product intended for rapid, mass administration following a nuclear incident. Operating as a private, pre-revenue entity, Captura is in the early development stage, targeting a niche but strategically important market driven by government and institutional preparedness programs. Its success hinges on navigating complex regulatory pathways and demonstrating efficacy in a field with limited treatment options.

Radiation Emergency MedicineMedical Countermeasures

Technology Platform

Oral chelation platform designed to bind and eliminate radioactive heavy metals and radionuclides from the gastrointestinal tract and bloodstream.

Opportunities

Significant unmet need in government and institutional emergency preparedness for nuclear/radiological incidents, driven by global nuclear energy reliance and geopolitical risks.

Potential for non-dilutive funding from U.S.

government agencies like BARDA and DoD.

First-mover advantage in developing an oral formulation for mass-casualty radionuclide decorporation.

Risk Factors

High regulatory hurdle under the FDA's Animal Rule requiring robust non-clinical efficacy and safety data.

Dependence on government procurement and stockpiling, a market subject to budgetary and political shifts.

Must demonstrate clear superiority over existing IV therapies to justify adoption and secure funding.

Competitive Landscape

Limited direct competition for an oral formulation; primary alternatives are intravenous chelating agents like Prussian blue (Radiogardase) and Ca-/Zn-DTPA. Competes for attention and funding within the broader biodefense sector. Potential future competition from other startups or government research programs targeting similar medical countermeasures.

More companies in Small Molecule Drugs →More companies in United States →